Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

MSC2364447C Phase 1b in Systemic Lupus Erythematosus
A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus Erythematosus
Status: Enrolling
Updated:  10/6/2017
Clinical Research Facility
mi
from
Saint Louis, MO
MSC2364447C Phase 1b in Systemic Lupus Erythematosus
A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus Erythematosus
Status: Enrolling
Updated: 10/6/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Academic Medical Research Institute
mi
from
Los Angeles, CA
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Academic Medical Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Mohamed A. El-Shahawy
mi
from
Los Angeles, CA
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Mohamed A. El-Shahawy
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
North Valley Nephrology
mi
from
Yuba City, CA
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
North Valley Nephrology
mi
from
Yuba City, CA
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Tulane University Hospital & Clinic
mi
from
New Orleans, LA
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Tulane University Hospital & Clinic
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Clinical Research Development Associates, LLC
mi
from
Springfield Gardens, NY
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Clinical Research Development Associates, LLC
mi
from
Springfield Gardens, NY
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Northeast Clinical Research Center, LLC
mi
from
Bethlehem, PA
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Northeast Clinical Research Center, LLC
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Medical University of South Carolina
mi
from
Charleston, SC
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Ramesh Gupta
mi
from
Memphis, TN
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Ramesh Gupta
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
UT Southwestern Medical Center at Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
IMMUNOe International Research Centers
mi
from
Centennial, CO
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
IMMUNOe International Research Centers
mi
from
Centennial, CO
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
University of Colorado
mi
from
Denver, CO
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated:  10/19/2017
Austin Health
mi
from
Heidelberg,
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis
Status: Enrolling
Updated: 10/19/2017
Austin Health
mi
from
Heidelberg,
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  10/24/2017
Clinical Research Facility
mi
from
Anniston, AL
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 10/24/2017
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  10/24/2017
Clinical Research Facility
mi
from
Orlando, FL
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 10/24/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  10/24/2017
Clinical Research Facility
mi
from
Great Neck, NY
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 10/24/2017
Clinical Research Facility
mi
from
Great Neck, NY
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  10/24/2017
Clinical Research Facility
mi
from
Birmingham, AL
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 10/24/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  10/24/2017
Clinical Research Facility
mi
from
Duncansville, PA
Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus
A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 10/24/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Anti-CD20 in Systemic Lupus Erythematosus
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status: Enrolling
Updated:  11/1/2017
University of Colorado
mi
from
Denver, CO
Anti-CD20 in Systemic Lupus Erythematosus
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status: Enrolling
Updated: 11/1/2017
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Anti-CD20 in Systemic Lupus Erythematosus
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status: Enrolling
Updated:  11/1/2017
University of Rochester
mi
from
Rochester, NY
Anti-CD20 in Systemic Lupus Erythematosus
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status: Enrolling
Updated: 11/1/2017
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Anti-CD20 in Systemic Lupus Erythematosus
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status: Enrolling
Updated:  11/1/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Anti-CD20 in Systemic Lupus Erythematosus
An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus
Status: Enrolling
Updated: 11/1/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Clearwater, FL
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Debary, FL
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Debary, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Miami Lakes, FL
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Miami, FL
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Orlando, FL
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Overland Park, KA
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Rochester, MN
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Manhasset, NY
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Duncansville, PA
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  11/16/2017
mi
from
Berlin,
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)
Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 11/16/2017
mi
from
Berlin,
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Achieve Clinical Research
mi
from
Birmingham, AL
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Achieve Clinical Research
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Southern California Permanente Medical Group
mi
from
Anaheim, CA
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Southern California Permanente Medical Group
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Wallace Rheumatic Study Center
mi
from
Los Angeles, CA
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Wallace Rheumatic Study Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Clinical Research of West Florida - Corporate
mi
from
Dunedin, FL
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Clinical Research of West Florida - Corporate
mi
from
Dunedin, FL
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Clinical Research of West Florida, Inc.
mi
from
Tampa, FL
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Clinical Research of West Florida, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
AA MRC LLC Ahmed Arif Medical Research Center
mi
from
Grand Blanc, MI
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
AA MRC LLC Ahmed Arif Medical Research Center
mi
from
Grand Blanc, MI
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
North MS Medical Clinics, Inc.
mi
from
Tupelo, MS
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
North MS Medical Clinics, Inc.
mi
from
Tupelo, MS
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Rutgers New Jersey Medical School
mi
from
Newark, NJ
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Rutgers New Jersey Medical School
mi
from
Newark, NJ
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
The Feinstein Institute for Medical Research
mi
from
Manhasset, NY
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Hospital for Special Surgery
mi
from
New York, NY
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
Box Arthritis and Rheumatology of the Carolina's
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/4/2017
MetroHealth System
mi
from
Cleveland, OH
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/4/2017
MetroHealth System
mi
from
Cleveland, OH
Click here to add this to my saved trials